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Treatment adherence and health outcomes in
patients with bronchiectasis
Amanda R McCullough1, Michael M Tunney1, Alexandra L Quittner2, J Stuart Elborn3, Judy M Bradley4
and Carmel M Hughes1*
Abstract
Background: We aimed to determine adherence to inhaled antibiotics, other respiratory medicines and airway
clearance and to determine the association between adherence to these treatments and health outcomes
(pulmonary exacerbations, lung function and Quality of Life Questionnaire-Bronchiectasis [QOL-B]) in bronchiectasis
after 12 months.
Methods: Patients with bronchiectasis prescribed inhaled antibiotics for Pseudomonas aeruginosa infection were
recruited into a one-year study. Participants were categorised as “adherent” to medication (medication possession
ratio ≥80% using prescription data) or airway clearance (score ≥80% in the Modified Self-Reported Medication-Taking
Scale). Pulmonary exacerbations were defined as treatment with a new course of oral or intravenous antibiotics
over the one-year study. Spirometry and QOL-B were completed at baseline and 12 months. Associations between
adherence to treatment and pulmonary exacerbations, lung function and QOL-B were determined by regression
analyses.
Results: Seventy-five participants were recruited. Thirty-five (53%), 39 (53%) and 31 (41%) participants were adherent
to inhaled antibiotics, other respiratory medicines, and airway clearance, respectively. Twelve (16%) participants were
adherent to all treatments. Participants who were adherent to inhaled antibiotics had significantly fewer exacerbations
compared to non-adherent participants (2.6 vs 4, p = 0.00) and adherence to inhaled antibiotics was independently
associated with having fewer pulmonary exacerbations (regression co-efficient = −0.51, 95% CI [−0.81,−0.21], p < 0.001).
Adherence to airway clearance was associated with lower QOL-B Treatment Burden (regression co-efficient = −15.46,
95% CI [−26.54, −4.37], p < 0.01) and Respiratory Symptoms domain scores (regression co-efficient = −10.77, 95% CI
[−21.45; −0.09], p < 0.05). There were no associations between adherence to other respiratory medicines and any of
the outcomes tested. Adherence to treatment was not associated with FEV1 % predicted.
Conclusions: Treatment adherence is low in bronchiectasis and affects important health outcomes including
pulmonary exacerbations. Adherence should be measured as part of bronchiectasis management and future research
should evaluate bronchiectasis-specific adherence strategies.
Keywords: Patient adherence, Bronchiectasis, Physical therapy, Drug therapy, Quality of Life Questionnaire-Bronchiectasis
Background
Non-cystic fibrosis (CF) bronchiectasis is an under-
researched condition with no licensed treatment therapies
[1]. Approximately 20% of the bronchiectasis population
are infected with Pseudomonas aeruginosa [2], which is
known to be associated with a more rapid decline in lung
function [3] and poorer health-related quality of life
(HRQoL) [4]. In line with published guidelines, inhaled
antibiotics along with other inhaled and oral medications
are commonly prescribed ‘off-label’ for these patients, with
the aim of reducing pulmonary exacerbations, maintaining
lung function and improving HRQoL [5]. Airway clear-
ance is also routinely prescribed for these patients leading
to a complex and burdensome treatment regimen.
Adherence to similar medications is consistently re-
ported to be low in asthma, chronic obstructive pulmonary
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disease (COPD) and CF, with approximately 50% of pa-
tients reported to be non-adherent [6-8]. Adherence to air-
way clearance is even lower than for medications, with up
to 70% of patients with CF non-adherent to this treatment
[9]. In bronchiectasis, a study exploring patients’ perspec-
tives on self-management reported that patients altered
their adherence to treatments [10]. A single study mea-
sured adherence in 22 patients with bronchiectasis pre-
scribed colistin delivered via I-neb® adaptive aerosol
delivery (Praxis Pharmaceuticals) or Pari LC® Plus and re-
ported high levels of adherence, with 73% of participants
categorised as adherent [11]. However, this study had a
small sample size, was retrospective, measured adherence
to Pari LC® Plus via self-report and did not determine if
adherence was associated with health outcomes.
Studies in asthma, COPD and CF demonstrate that low
adherence to treatment can negatively impact on key
health outcomes including pulmonary exacerbations [8,12],
HRQoL [6,13] as well as healthcare costs [14,15]. The first
randomised controlled trial investigating the effectiveness
of colistin (Promixin®) in bronchiectasis has shown that it
is effective in delaying time to first pulmonary exacerbation
and improving HRQoL when patients are adherent i.e. in-
hale between 81–92.1% of prescribed medication [16].
Thus, rates of adherence to treatment may affect important
health outcomes such as pulmonary exacerbations, lung
function and HRQoL in bronchiectasis. Rates of treatment
adherence and the effect of treatment adherence on these
health outcomes in bronchiectasis are not known. With
large-scale studies of new and potentially expensive therap-
ies that have been tailored for use in patients with bronchi-
ectasis infected with P. aeruginosa underway [16,17], it is
important to determine treatment adherence in this popu-
lation to ensure that adherence is maximised prior to the
prescription of these new therapies.
Thus, the primary aim of this one-year study was to
determine rates of treatment adherence (inhaled antibi-
otics, other respiratory medicines and airway clearance)
in patients with bronchiectasis infected with P. aerugi-
nosa over the year-long study. The secondary aim was to
determine the association between adherence to treatment
and health outcomes (pulmonary exacerbations, lung
function and Quality of Life Questionnaire-Bronchiectasis
[QOL-B]) in this population after 12 months. It was
hypothesised that adherence would be low and patients
who were adherent to inhaled antibiotics would have
fewer pulmonary exacerbations.
Methods
Participants
Participants were recruited from the Regional Respiratory
Centre at Belfast City Hospital and from seven secondary
care hospitals across Northern Ireland (June 2010-August
2011). Adult patients with a confirmed diagnosis of
bronchiectasis by high-resolution computed tomog-
raphy, who commenced inhaled colistin or tobramycin
by nebuliser ≥6 weeks prior to recruitment and had a
positive sputum culture for P. aeruginosa prior to start-
ing inhaled antibiotics, were recruited (Additional file 1
contains a copy of the patient information sheet). Par-
ticipants had to be clinically stable (≥2 weeks post com-
pletion of treatment for a pulmonary exacerbation)
prior to data collection. Ethical approval was obtained
from the Office for Research Ethics Northern Ireland
(10/NIR03/17). All participants provided written informed
consent. As part of usual care in all centres, participants
had received training from a specialist nurse and/or
physiotherapist on how to use nebulisers and inhalers.
All participants received education about how to complete
airway clearance from a specialist physiotherapist. All par-
ticipants were routinely followed-up by respiratory consul-
tants and/or nursing/physiotherapy.
Study design
A one-year study was conducted (June 2010-August
2012). Data were collected at baseline followed by 3 or 6
monthly intervals.
A modified version of the Self-reported Medication-
taking Scale [18] including an additional question [19]
(e-Table 1, Additional file 1) was interviewer-administered
in person (baseline, 6 and 12 months) or via telephone (3
and 9 months) for each treatment: inhaled antibiotics,
other respiratory medicines (e.g. inhaled corticosteroids or
oral azithromycin) and airway clearance. Each question-
naire contained five questions which were answered either
‘yes’ (scored as 0) or ‘no’ (scored as 1) (e-Table 1). The
maximum score was of 5, with higher scores indicating
higher adherence. Participants were categorised as adher-
ent to each treatment by scoring ≥4 (≥80%) on this scale
at all data collection points. There is no consensus in the
literature about an appropriate cut-off for adherence as
thresholds for treatment efficacy are not known. However,
landmark bronchiectasis clinical trials consistently use
80% as their threshold for adherence [17,20] and the 80%
cut-off has been shown to offer the optimal balance be-
tween specificity and sensitivity for self-reported, prescrip-
tion refill and electronic pillbox adherence measures [19].
Data on prescribed medications including dosages were
extracted from medical records and provided by patients
on a 6 monthly basis and used to maintain an up-to-date
list of prescribed medication. Participants provided us
with contact details for all of the community pharmacies
who dispensed their medications for bronchiectasis. In a
minority of cases, participants obtained their inhaled anti-
biotics from a hospital pharmacy (n = 12). The researcher
contacted participants’ community and hospital pharma-
cies on a 6 monthly basis to obtain a list of dispensed
medications for the previous 6 months. All pharmacies
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contacted provided a full list of dispensed medication
for the duration of the participant’s inclusion in the
study i.e. from baseline until each participant completed
the study at one year. We did not collect data on medi-
cation carryover pre-baseline or leftover at the end of
the study period [8,14].
Medication possession ratios (MPRs) were calculated
for inhaled antibiotics and other respiratory medicines
from the medication data described above, using the
number of days’ supply divided by the number of days
medication was prescribed in the study (from baseline
until each participant completed the study at one year)
and multiplied by 100 [8,14,21]. MPR was calculated
over the year rather than 6 monthly to reduce the effect
of any carryover/left-over as this is likely to average out
over this time [22] and to reduce the effect that seasonal
variation in symptoms might have on adherence and
health outcomes. Participants were expected to be in the
study for 365 days with most participants completing
within one week of this end date; however, this varied
slightly due to patients experiencing pulmonary exacer-
bations which delayed final data collection. We did not
exclude days of hospital admission as participants used
their own medications whilst in hospital (standard prac-
tice in the included hospitals). MPR was calculated with
and without removing hospital admission days and this
did not result in a change of adherence categorisation
for any participant. Therefore, the MPR used in this ana-
lysis was calculated based on the assumption that partic-
ipants used their own medications in hospital to reduce
the risk of over-estimating adherence. New medications
commenced in hospital were provided by the hospital
during stays and issued from community pharmacies on
discharge. To accurately calculate the total number of
days in the study for a new medication which was
Table 1 Baseline characteristics of study participants
(n = 75)
Characteristic Result
Age, yr 64 ± 8
Gender, M/F 24 (32)/51 (68)
Occupational status, n (%) Employed/self-employed 18 (24)
Retired 57 (76)
Level of education, n (%) Less than high school 14 (19)
High school 54 (72)
University 7 (9)
Marital status, n (%) Married or
with a partner
57 (76)
Not married or not
with a partner
18 (24)
FEV1, L 1.34 ± 0.6
FEV1,% predicted 61 ± 25
Smoking status, n (%) Never 53 (71%)
Current or ex 22 (29%)
Aetiology, n (%) Post-infection 32 (43%)
Idiopathic 16 (21%)
Rheumatoid arthritis 8 (11%)
COPD 5 (7%)
Asthma 3 (4%)
Other 11 (15%)
Prescribed medicines 12 ± 5
Inhaled antibiotics, n (%) Colistin 64 (85%)
Tobramycin 11 (15%)
Other respiratory
medicines, n (%)
Oral medicines Azithromycin 38 (51%)
Oral steroids 19 (25%)
Mucolytics 10 (13%)
Leukotriene receptor
antagonists
8 (11%)
Theophylline 7 (9%)
Co-trimoxazole 1 (1%)
Salbutamol 1 (1%)
Inhaled medicines Short-acting beta2 agonists 67 (89%)
Inhaled corticosteroids 65 (87%)
Antimuscarinics 31 (41%)
Long-acting beta2 agonists 2 (3%)
Nebulised medicines Short-acting beta2 agonists 55 (73%)
Isotonic saline 25 (33%)
Ipratropium bromide
with salbutamol
3 (4%)
Hypertonic saline 1 (1%)
Budesonide 1 (1%)
Airway clearance 39 (53%)
Table 1 Baseline characteristics of study participants
(n = 75) (Continued)
Active cycle of
breathing technique
Acapella® 45 (61%)
QOL-B Physical functioning 31 ± 26
Role functioning 45 ± 28
Vitality functioning 37 ± 20
Social functioning 42 ± 26
Emotional functioning 73 ± 21
Treatment burden 56 ± 20
Health perceptions 39 ± 19
Respiratory symptoms 53 ± 21
Results are presented as mean ± SD or n (%).
COPD: chronic obstructive pulmonary disease.
QOL-B: Quality of Life Questionnaire-Bronchiectasis; scores range 0–100, higher
scores indicate better quality of life.
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commenced in hospital, the number of days between the
start and end date of the medication was calculated and
the number of days supplied by the hospital was sub-
tracted from this.
When participants were prescribed oral or intravenous
(IV) antibiotics, some healthcare professionals advised
participants to stop their inhaled antibiotics and/or azi-
thromycin during this time. Therefore, depending on
local policy, when calculating MPR for inhaled antibi-
otics and azithromycin, the number of days of IV and/or
oral antibiotic usage was deducted from the number of
days medication was prescribed in the study.
For adherence to other respiratory medicines, MPR
was calculated for each individual medication as de-
scribed above and then averaged for each participant to
give a composite MPR for ‘other respiratory medicines’
[8,14]. MPR for ‘other respiratory medicines’ did not in-
clude salbutamol nebulisers or inhalers. Participants who
had an MPR ≥80% were categorised as adherent for in-
haled antibiotics and other respiratory medicines [8].
A pulmonary exacerbation was defined as a new admin-
istration of oral or intravenous (IV) antibiotics for a re-
spiratory infection [23]. Participants kept a record of oral
and IV antibiotic usage and hospital admissions for bron-
chiectasis for the duration of the study and these were
cross-referenced with participant medical records and
prescription data. To take account of potential clustering
of pulmonary exacerbations [24], antibiotics administered
within 14 days of the end of a previous course of antibi-
otics were considered to be a continuation of the previous
pulmonary exacerbation and not classified as a new pul-
monary exacerbation [25]. This cut-off for exacerbations
reflects data in COPD which demonstrates that it takes
14 days to recover from an exacerbation [26]. No similar
data exist for bronchiectasis.
Spirometry was performed according to accepted guide-
lines at baseline and 12 months [27]. Participants self-
completed the Quality of Life Questionnaire-Bronchiectasis
(QOL-B) (version 2.0, 2008) at baseline and 12 months
[28]. This version contained 45 questions. Further revisions
were made by the authors (version 2.1, 2010), which re-
moved 10 questions that patients did not perceive as rele-
vant and added one question ‘I am worried about being
exposed to others who are sick’ (scored on the Social Func-
tioning domain). The 10 questions that were removed were
not scored and the wording of the remaining questions be-
tween version 2.0 (2008) and version 2.1 (2010) was un-
changed. The scoring of the questionnaire allows for one
missing response in each domain; therefore, the addition of
a new question did not impact the scoring for the Social
Functioning domain for those who had already completed
the previous version at baseline (n = 48). Version 2.1 (2010)
was used for all other study time points. Standardized
scores were calculated for the 8 scales of the QOL-B
(Physical Functioning, Role Functioning, Vitality, Social
Functioning, Emotional Functioning, Treatment Burden,
Health Perceptions, Respiratory Symptoms), ranging from
0–100 for each domain; higher scores indicate better
HRQoL. No total score is calculated. Psychometric proper-
ties of the QOL-B are discussed in Additional file 1.
Statistical analysis
Assuming that adherence to inhaled medication was low
in this patient group, in order to detect a difference of 2
exacerbations at 80% power and 5% significance, approxi-
mately 100 participants needed to be recruited, assuming
that 80% were non-adherent and 20% were adherent. This
study was conducted across 8 sites to maximise recruit-
ment; despite this, there were insufficient numbers of eli-
gible participants to meet the recruitment target within
the study timeframe. However, the study was not under-
powered to detect a difference in the frequency of pul-
monary exacerbations (see details in the Discussion).
Data were included up until completion or withdrawal
from the study and were entered into IBM SPSS for Win-
dows, version 19 (IBM Corp, Armonk, NY). Between-
group differences in adherence were calculated for
pulmonary exacerbations, lung function at 12 months
and QOL-B at 12 months using t tests. These analyses
were completed using MPR for medication adherence and
self-report for airway clearance adherence. A Poisson re-
gression model with adherence to inhaled antibiotics,
other respiratory medicines and airway clearance entered
as independent variables and pulmonary exacerbations as
the dependent variable was completed. A standard linear
regression model with adherence to inhaled antibiotics,
other respiratory medicines and airway clearance entered
as independent variables was completed for each of the
following outcomes: 12 month FEV1 % predicted,
12 month QOL-B Treatment Burden and Respiratory
Symptoms domains. We did not complete regression
models to determine associations between adherence and
all eight QOL-B domains to limit the chance of type 1
error. We chose QOL-B Treatment Burden and Respira-
tory Symptoms as Treatment Burden is important for ad-
herence in CF [9] and QOL-B Respiratory Symptoms is a
recognised end-point for bronchiectasis clinical trials [29].
All models were adjusted for age, gender and baseline
FEV1 % predicted. If any of the adherence groups in any
of the models were significant or borderline significant (p
< 0.1), we re-ran the models with that one omitted to
check for ‘masking’ of effects of the other two groups.
Results
Study participants
Seventy-five of 108 (69%) potentially eligible participants
were recruited, with 69 completing the one-year study
(Figure 1). Participants were in the study for a mean ±
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SD of 355 ± 72 days. Participants’ baseline demographic,
disease-specific, medication, airway clearance and QOL-
B data are shown in Table 1.
Adherence to treatment
More participants self-reported adherence to inhaled an-
tibiotics (50/75 participants [67%]) and other respiratory
medicines (45/74 participants [61%]) than was recorded
using MPRs (inhaled antibiotics: 35/66 [53%] and other
respiratory medicines: 39/73 [53%]) (Table 2). Airway
clearance had the lowest rate of adherence (self-report),
with 31/75 (41%) participants categorised as adherent.
This was significantly lower than adherence to inhaled
antibiotics (p = 0.00) and other respiratory medicines (p =
0.01). Overall, only 12 (16%) participants were categorised
as adherent to all prescribed treatments and 16 (21%)
were categorised as non-adherent to all treatments.
Health outcomes
Participants had a mean ± SD 3.2 ± 2 pulmonary exacerba-
tions during the study. Mean ± SD FEV1 (1.36 L ± 0.55)
and FEV1, % predicted (63% ± 26) at 12 months were not
significantly different from baseline. Mean ± SD 12 month
QOL-B Physical Functioning (34 ± 27), Role Functioning
(49 ± 25), Vitality (40 ± 21), Social Functioning (41 ± 25),
Emotional Functioning (75 ± 20), Treatment Burden (60 ±
22), Health Perceptions (41 ± 17), Respiratory Symptoms
(57 ± 21) scores were not significantly different from
baseline.
Figure 1 Flow of participants through the study from recruitment to completion.
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Treatment adherence and health outcomes
Differences in health outcomes between adherence groups
are summarised in Table 2. Participants who were adher-
ent to inhaled antibiotics had significantly fewer pulmon-
ary exacerbations and participants who were adherent to
airway clearance had significantly higher QOL-B Physical
Functioning scores (Table 2). No other significant dif-
ferences between those who were adherent and non-
adherent were noted.
Regression models for adherence and health outcomes
are shown in Tables 3, 4, 5 and 6. Adherence to inhaled
antibiotics was associated with having fewer pulmonary
exacerbations (regression co-efficient = −0.51, 95% CI
[−0.81,-0.21], p < 0.001). Adherence to other respiratory
medicines and airway clearance were not associated with
pulmonary exacerbations. Adherence to treatment was
not associated with FEV1 % predicted. Adherence to air-
way clearance was associated with having a lower QOL-
B Treatment Burden score i.e. higher treatment burden
(regression co-efficient = −15.46, 95% CI [−26.54, −4.37],
p < 0.01). Adherence to inhaled antibiotics and other re-
spiratory medicines were not associated with QOL-B
Treatment Burden score. Adherence to airway clearance
was associated with lower Respiratory Symptoms domains
scores i.e. more problematic symptoms (regression co-
efficient = −10.77, 95% CI [−21.45; −0.09], p < 0.05). Ad-
herence to inhaled antibiotics and other respiratory
medicines were not associated with QOL-B Respiratory
Symptoms score.
Discussion
In this one-year study, treatment adherence was low in
patients with bronchiectasis prescribed inhaled antibi-
otics for P. aeruginosa infection. The reported MPR ad-
herence rates of 53% for inhaled antibiotics and other
respiratory medicines and 41% for airway clearance
(based on self-report) are comparable to studies in
asthma, COPD and CF [6-8] but lower than previously
reported in bronchiectasis [11,16]. MPR is a more reli-
able method of adherence measurement than self-report
Table 2 Comparison between adherence groups for health outcomes measured during the one-year study
Inhaled antibiotics Other respiratory medicines Airway clearance
(n = 61a) (n = 68b) (n = 69c)
Adherent
(n = 32)
Non-adherent
(n = 29)
p Adherent
(n = 37)
Non-adherent
(n = 31)
p Adherent
(n = 27)
Non-adherent
(n = 42)
p
Pulmonary
exacerbationsd
2.6 ± 2 4.0 ± 2 0.00* 3.1 ± 2.2 3.3 ± 2.3 0.75 3.1 ± 2.2 3.2 ± 2.2 0.84
FEV1, L at
12 months
1.36 ± 0.54 1.29 ± 0.51 0.61 1.35 ± 0.59 1.35 ± 0.50 0.97 1.29 ± 0.44 1.41 ± 0.61 0.40
FEV1,% predicted
at 12 months
65 ± 28 56 ± 23 0.22 63 ± 30 63 ± 22 0.92 65 ± 23 62 ± 29 0.60
QOL-B at
12 months
Physical
Functioning
33 ± 28 31 ± 24 0.77 29 ± 26 39 ± 28 0.13 42 ± 28 29 ± 26 0.05*
Role Functioning 48 ± 27 45 ± 21 0.63 44 ± 24 55 ± 24 0.06 48 ± 23 50 ± 26 0.79
Vitality 39 ± 22 39 ± 20 0.92 40 ± 20 40 ± 22 0.98 39 ± 23 40 ± 20 0.73
Social
Functioning
42 ± 28 41 ± 22 0.89 39 ± 26 43 ± 25 0.46 37 ± 22 44 ± 27 0.25
Emotional
Functioning
73 ± 21 76 ± 18 0.60 74 ± 20 76 ± 20 0.69 73 ± 23 76 ± 18 0.49
Treatment
Burden
59 ± 22 57 ± 21 0.83 61 ± 25 59 ± 20 0.66 54 ± 22 64 ± 22 0.07
Health
Perceptions
40 ± 18 39 ± 13 0.80 40 ± 18 42 ± 16 0.71 40 ± 19 41 ± 16 0.79
Respiratory
Symptoms
61 ± 21 51 ± 20 0.06 60 ± 22 53 ± 20 0.15 54 ± 20 58 ± 22 0.42
an = 61: 6 withdrawals, 8 without adequate adherence data.
bn = 68: 6 withdrawals, 1 participant not prescribed treatment.
cn = 69: 6 withdrawals.
dinhaled antibiotics: n = 66: 1 participant withdrawal, 8 participants with insufficient data to calculate adherence; other respiratory medicines n = 73: 1 participant
withdrawal, 1 not prescribed; airway clearance n = 74: 1 participant withdrawal.
*p < 0.05.
Results are presented as mean ± SD, median (IQR) or percentage.
FEV1: forced expiratory volume in one second.
QOL-B: Quality of Life Questionnaire-Bronchiectasis; scores range 0–100, higher scores indicate better quality of life.
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in observational studies conducted in a ‘real-life’ setting
[13]; however, it still has the potential to over-estimate
adherence [8], making these findings even more clinic-
ally concerning. At present, treatment adherence is not
routinely assessed in bronchiectasis. We have demon-
strated that it is possible to collect these data within a
‘real-life’ setting and are aware that some centres already
have access to pharmacy claims data; therefore, potential
methods of objectively monitoring adherence in clinical
practice are on the horizon. With the prescription of
new and potentially expensive therapies for bronchiectasis,
particularly for those infected with P. aeruginosa [16,17],
monitoring of adherence is likely to become an increas-
ingly important aspect of bronchiectasis management.
We studied adherence to three different treatments
and found that these treatments had different effects on
the health outcomes studied. Similar to findings of other
longitudinal adherence studies in CF and COPD [8,12],
participants who were adherent to inhaled antibiotics
had fewer pulmonary exacerbations, with nearly twice as
many exacerbations in the non-adherent group. This is a
significant finding given that exacerbations are thought
to be associated with disease progression in this popula-
tion [1]. Whilst the current study did not aim to deter-
mine the efficacy of inhaled antibiotics, it did indicate
that inhaled antibiotics may be effective in reducing pul-
monary exacerbations in bronchiectasis when ≥80% of
prescribed medication is consumed. These findings, taken
together with the recently reported colistin findings, have
important implications for future inhaled antibiotics stud-
ies and for the monitoring of adherence to inhaled antibi-
otics in clinical practice [16]. We cannot discern the
direction of the relationship between adherence and
pulmonary exacerbations from our data and further re-
search to better understand this relationship is needed.
Table 3 Poisson regression model for the association
between adherence and pulmonary exacerbationsa
Independent variables Estimated
co-efficient (SE)
95% CI
Adherence to inhaled antibioticsb −0.51*** (0.15) [−0.81; −0.21]
Adherence to other
respiratory medicinesb
0.06 (0.15) [−0.24; 0.36]
Adherence to airway clearanceb 0.04 (0.15) [−0.25; 0.33]
Age −0.01 (0.01) [−0.02; 0.01]
Genderc 0.17 (0.15) [−0.14; 0.47]
Baseline FEV1 % predicted 0.01 (0.00) [0.00; 0.01]
an = 65: 1 participant withdrawal, 8 participants with insufficient data to
calculate adherence to inhaled antibiotics and 1 participant not prescribed
other respiratory medicines.
bAdherent = 1, non-adherent = 0.
cMale = 1, female = 0.
***p < 0.001.
Table 4 Linear regression model for the association
between adherence and FEV1 % predicted
a
Independent variables Estimated
co-efficient (SE)
95% CI
Adherence to inhaled antibioticsb −2.03 (2.57) [−7.06; 3.00]
Adherence to other
respiratory medicinesb
4.43 (2.57) [−0.61; 9.47]
Adherence to airway clearanceb −2.32 (2.47) [−7.16; 2.51]
Age −0.11 (0.15) [−0.40; 0.17]
Genderc −5.05 (2.64) [−10.23; 0.13]
Baseline FEV1 % predicted 1.04*** (0.05) [0.94; 1.15]
an = 60: 6 participant withdrawals,, 8 participants with insufficient data to
calculate adherence to inhaled antibiotics and 1 participant not prescribed
other respiratory medicines.
bAdherent = 1, non-adherent = 0.
cMale = 1, female = 0.
***p < 0.001.
Adjusted R2 = 0.07.
Table 5 Linear regression model for the association
between adherence and 12 month QOL-B Treatment
Burdena
Independent variables Estimated
co-efficient (SE)
95% CI
Adherence to inhaled antibioticsb −0.01 (5.88) [−11.53; 11.51]
Adherence to other
respiratory medicinesb
−4.22 (5.89) [−15.77; 7.34]
Adherence to airway clearanceb −15.46** (5.66) [−26.54; −4.37]
Age 0.79* (0.33) [0.14; 1.45]
Genderc 10.87 (6.05) [−0.72; 24.34]
Baseline FEV1% predicted 0.16 (0.12) [−0.09; 0.40]
an = 60: 6 participant withdrawals, 8 participants with insufficient data to
calculate adherence to inhaled antibiotics and 1 participant not prescribed
other respiratory medicines.
bAdherent = 1, non-adherent = 0.
cMale = 1, female = 0.
**p < 0.01, *p < 0.05.
Adjusted R2 = 0.13.
Table 6 Linear regression model for the association
between adherence and 12 months QOL-B respiratory
symptomsa
Independent variables Estimated
co-efficient (SE)
95% CI
Adherence to inhaled antibioticsb 8.13 (5.66) [−2.96; 19.22]
Adherence to other
respiratory medicinesb
−1.94 (5.68) [−13.06; 9.19]
Adherence to airway clearanceb −10.77* (5.45) [−21.45; −0.09]
Age 0.92** (0.32) [0.29; 1.55]
Genderc 7.74 (5.83) [−3.68; 19.17]
Baseline FEV1% predicted 0.07 (0.12) [−0.16; 0.31]
an = 60: 6 participant withdrawals,, 8 participants with insufficient data to
calculate adherence to inhaled antibiotics and 1 participant not prescribed
other respiratory medicines.
bAdherent = 1, non-adherent = 0.
cMale = 1, female = 0.
**p < 0.01, *p < 0.05.
Adjusted R2 = 0.16.
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Approximately half of our participants were non-adherent
to inhaled antibiotics. Therefore, irrespective of the direc-
tion of this relationship, interventions to improve adher-
ence are likely to reduce the frequency of these critical
pulmonary events and their associated costs.
The lack of association between adherence and FEV1
% predicted is not surprising in this population, given
the growing evidence that FEV1 is not a sensitive meas-
urement of lung function in bronchiectasis [1,30]. Fur-
thermore, the effectiveness of the treatments included in
this study on maintaining or reducing FEV1 decline is
not known.
Our mean QOL-B domain scores were all lower than
those reported in the recent QOL-B paper, particularly for
Physical and Role Functioning and Treatment Burden
[28]. Inhaler preparations of antibiotics delivered via in-
haler rather than nebuliser (e.g. ciprofloxacin dry powder
inhaler [17]) may offer a potential method of reducing
treatment burden in these patients with bronchiectasis.
Inhaler delivery of antibiotics may improve adherence for
those in whom time and effort are barriers to treatment.
However, it is well recognised that adherence to inhalers
in COPD and asthma is approximately 50% in most stud-
ies [6,7]. For others, such as those worried about long
term use of antibiotics, an inhaler preparation of antibi-
otics will not be sufficient to overcome these barriers to
adherence.
Our results demonstrated that adherence to airway
clearance was associated with a higher burden of treat-
ment and worse respiratory symptoms as measured by
QOL-B. These findings may appear counter-intuitive
when compared to findings in CF [9]; however, the Treat-
ment Burden domain asks patients about the amount of
time they commit to their treatments on a daily basis;
therefore, those who adherent are likely to spend longer
on treatment and may report a higher treatment burden.
The relationship between perceived symptoms and adher-
ence is not clear-cut and there are many papers reporting
conflicting results [6,8,12,15]. We have recently reported
that a lack of belief about necessity for treatment can in-
fluence adherence decision-making for airway clearance,
particularly when patients do not experience troublesome
symptoms [31]. Thus, it could be that this relationship re-
flects this finding, in that those with more symptoms may
be more likely to adhere.
We did not find any association between adherence to
inhaled antibiotics or other respiratory medicines and
the QOL-B domains studied. This is similar to results
from studies exploring associations between adherence
to treatment and HRQoL in other chronic respiratory
disease populations which have reported conflicting re-
sults [6,8,12,15]. The inconsistent effects of medications
on HRQoL of patients with bronchiectasis may go some
way to explaining this finding. Some medications such
as colistin and azithromycin are associated with better
HRQoL [16,32] whilst no significant improvement in
HRQoL was reported for erythromycin [33]. In addition,
the composite nature of the MPR value for ‘other re-
spiratory medicines’ may also have masked any relation-
ships between individual medications (e.g. azithromycin)
and QOL-B.
We have recently reported that adherence decision-
making in bronchiectasis involves patients weighing up
the pros and cons of adhering to treatment [31]. The
prescription of medications ‘off-label’ and without proven
efficacy may be influencing this decision-making process,
as patients may not perceive there to be any benefits of
the prescribed treatments [31]. This may be particularly
true for inhaled corticosteroids, which are generally not
recommended for prescription for bronchiectasis [5] but
which were prescribed for 87% of the participants in this
study. Thus, there is an urgent need for efficacy studies in
this population so that as we begin to focus on improving
adherence, we do so for efficacious treatments.
This study was based in a ‘real life’ setting and the cost
and lack of availability of electronic monitoring in clin-
ical practice plus its potential behaviour altering effect
precluded its inclusion in this study. Therefore, MPRs
offered an accurate and feasible method of measuring
medication adherence [13]. It is accepted that MPR may
overestimate medication adherence as it does not con-
firm ingestion or inhalation [8]. Carryover and leftover
were not included in our MPR calculations; however, the
duration of the follow-up period of our study may have
reduced the effect of any carryover/left-over as this is
likely to average out over time [22]. We collected MPR
data on a 6 monthly basis; however, we only calculated
MPR over the year of the study rather than 6 monthly to
reduce the effect that seasonal variation in symptoms
might have on adherence and health outcomes. A cut-
off of 80% to denote adherence and non-adherence is
commonly used in the adherence literature and in land-
mark bronchiectasis clinical trials [17,20]. Furthermore,
the 80% cut-off has been shown to offer the optimal bal-
ance between specificity and sensitivity for self-reported
and prescription refill adherence measures [19].
The primary limitation of this study was its sample
size. We did not reach the target of 100 participants
within the study sites and timeframe. However, the study
was not underpowered to detect a difference in pulmon-
ary exacerbations and the sample size is similar to re-
cently reported studies in bronchiectasis [32,33]. The
study analysed the associations between adherence data
collected over one year with health outcome data col-
lected at one data collection point (12 months). This did
not allow us to explore the variability within adherence
during the study or to analyse the effect of adherence on
outcomes at other time points e.g. 6 months after
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baseline. In most cases, participants used a regular com-
munity pharmacy to dispense all of their medications for
bronchiectasis; however, it is possible that some data
may have been missing if a participant or carer used a
different pharmacy to those contacted. We minimised
this by asking participants to provide an up-to-date list
at each visit of all of the pharmacies they used and the
researcher contacted all of these pharmacies. This study
only included patients infected with P. aeruginosa, who
constitute approximately 20% of the bronchiectasis
population [2]. These patients tend to be sicker than
other patients with bronchiectasis [3,4]. However, the
mean age of 64 years, predominance of women, and the
moderate impairment in lung function suggested that
our sample was representative of the bronchiectasis
population [2].
Conclusions
This is the first study to demonstrate that adherence is
low in bronchiectasis and that it affects important health
outcomes including pulmonary exacerbations. Therefore,
adherence assessment and monitoring should be consid-
ered an integral part of the management of patients with
bronchiectasis to ensure that treatment interventions are
optimised. Future research should explore reasons for
non-adherence and evaluate bronchiectasis-specific strat-
egies to enhance adherence in these patients.
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